Сравнение

Pasireotid vs. Terlipressin

Два пептида рядом — идентичность, доказательная база, правовой статус и известные нежелательные явления.

Идентичность

Категория

Исследования (прочее)

Номер CAS

396091-73-9

14636-12-5

Молекулярная масса

1047.21 g/mol

1227.37 g/mol

Период полувыведения

нет данных

Последовательность

нет данных

Механизм действия

Pasireotid

Pasireotide binds more broadly than older somatostatin analogs (SSTR1/2/3/5) with particularly high affinity for SSTR5. This suppresses, among others, ACTH release in Cushing's disease and GH release in acromegaly.

Terlipressin

Terlipressin is slowly converted in the body to lysine-vasopressin by cleavage of the three N-terminal glycyl residues (reservoir effect) and activates V1 receptors. The splanchnic vasoconstriction improves renal perfusion in hepatorenal syndrome.

Доказательная база

Наивысшая доказательность

РКИ на людях

Исследования

из них на людях

Зафиксированные эффекты

Открытые противоречия

Задокументированные нежелательные явления

Правовой статус

Country	Pasireotid	Terlipressin
Германия	Рецептурный	Рецептурный
США	Рецептурный	Рецептурный

Полные записи

Frequently asked questions

What is the difference between Pasireotid and Terlipressin?: Pasireotid is classified as "Исследования (прочее)", while Terlipressin is classified as "Исследования (прочее)". Pasireotid: Pasireotide is a multireceptor somatostatin analog binding to four of the five somatostatin receptors (especially SSTR5). It is approved for Cushing's disease and acromegaly. Terlipressin: Terlipressin is a 12-amino-acid vasopressin analog and prodrug of lysine-vasopressin. As a V1 receptor agonist it is vasoconstrictive and is approved for hepatorenal syndrome (FDA 2022, Terlivaz). This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Pasireotid or Terlipressin?: The highest available evidence level is "РКИ на людях" for Pasireotid and "РКИ на людях" for Terlipressin. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Pasireotid and Terlipressin in Germany and the United States?: Германия: Pasireotid — Рецептурный, Terlipressin — Рецептурный. США: Pasireotid — Рецептурный, Terlipressin — Рецептурный. These are factual summaries with source and review date on the individual pages.

Country

Pasireotid

Terlipressin

Германия

Рецептурный

США

Рецептурный

Frequently asked questions

What is the difference between Pasireotid and Terlipressin?

Pasireotid is classified as "Исследования (прочее)", while Terlipressin is classified as "Исследования (прочее)". Pasireotid: Pasireotide is a multireceptor somatostatin analog binding to four of the five somatostatin receptors (especially SSTR5). It is approved for Cushing's disease and acromegaly. Terlipressin: Terlipressin is a 12-amino-acid vasopressin analog and prodrug of lysine-vasopressin. As a V1 receptor agonist it is vasoconstrictive and is approved for hepatorenal syndrome (FDA 2022, Terlivaz). This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Pasireotid or Terlipressin?

The highest available evidence level is "РКИ на людях" for Pasireotid and "РКИ на людях" for Terlipressin. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Pasireotid and Terlipressin in Germany and the United States?

Германия: Pasireotid — Рецептурный, Terlipressin — Рецептурный. США: Pasireotid — Рецептурный, Terlipressin — Рецептурный. These are factual summaries with source and review date on the individual pages.